I had kicked the tires on WTX.ST before but ultimately chose to pass, in part, due to a competitive threat from private French gene therapy player Vivet Therapeutics: https://www.vivet-therapeutics.com/en . They have a gene therapy for Wilson's disease that is set to enter the clinic 4Q this year with PoC data expected around the time of the pivotal P3 data for WTX.ST's drug (WTX101) in 2H19. Evidently, ALXN doesn't view Vivet's gene therapy as a serious threat.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.